skip to Main Content

Federal government awards the University of Toronto $114-million regenerative medicine grant

University of TorontoOn Tuesday, July 28, 2015, the federal government announced a $114-million grant to cement the University of Toronto‘s position as one of the world’s leading centres for the design and manufacture of cells, tissues and organs to treat degenerative disease.

This announcement was covered in The Globe & Mail and Lab Products News, and by CBC.ca, CTV News and Global TV. MaRS Innovation was specifically mentioned as a commercialization partner in the Toronto Star‘s coverage.

As the university’s commercialization agent, MaRS Innovation welcomes this news and the downstream companies and technology licenses it will create. The Honourable Ed Holder, Minister of State (Science and Technology), made the announcement.

The funding will allow U of T, in partnership with its research partners and fellow MI members — The Hospital for Sick Children, the University Health Network and Mount Sinai Hospital — to conduct transformational research and clinical translation in regenerative medicine, enhance capability in synthetic biology and computational biology and foster translation, commercialization and clinical impacts.

Continue Reading

Dr. Raphael Hofstein in Biotechnology Focus: It’s time to declare an end to Canada’s two research solitudes

Dr. Raphael Hofstein
Dr. Raphael Hofstein, president & CEO, MaRS Innovation.

Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by Dr. Raphael Hofstein, MaRS Innovation’s president & CEO, and Elizabeth Monier-Williams, director of marketing and communications.

The article explores the way research focused on discovery and commercialization are often viewed or positioned as competitors within the funding ecosystem and the need to align their goals:

The time of Canada’s French and English solitudes may be past, as Governor General Michaëlle Jean notably stated when she took office in 2005, but the solitudes of thought concerning how Canada supports basic and commercial research persist.

This thinking is most easily spotted after the government announces a federal budget, triggering a flurry of opinion pieces debating the breakdown for the $2.7 billion Canada spends on research.

Most recently, Jim Balsillie, co-founder of Research in Motion (now BlackBerry Ltd.), wrote for the Globe & Mail about the Canadian need to understand that “geopolitics is at the heart of commercializing ideas,” and create better policies to protect Canadian ideas, including “better
incentives for researchers to spur commercialization,” such as during an academic’s consideration for tenure. Yet, like any business endeavor whose success depends on people, there’s more involved in changing Canada’s approach to commercialization than just policy.

The people must want to change, too.

Continue Reading

Globe and Mail features UTEST company eQOL’s home dialysis technology

EQOL logo“When Binh Nguyen, then a graduate student in biomedical engineering at the University of Toronto, was working in the renal engineering department of a local hospital, he was struck by what he felt was a suboptimal setup for dialysis treatment,” writes Jordana Dixon in “Health startup helps patients become more independent,” for the Globe and Mail on April 13, 2015.

eQOL Inc. is a University of Toronto and MaRS Innovation start-up company that participated in and graduated from the University of Toronto Early-Stage Technology (UTEST) program’s second cohort.

UTEST is currently accepting applications for its fourth cohort.

Here’s an excerpt from the article:

Taking these complications into consideration, Mr. Nguyen envisioned an all-encompassing lateral system that would optimize the process of in-home dialysis utilizing technology, but most importantly, improving patient experience.

Continue Reading

How to get accepted into the UTEST start-up incubator: Drive and differentiation

UTEST is now accepting applications to Cohort 4

utestEditor’s note: As of today, the University of Toronto Early-Stage Technology (UTEST) program, which MaRS Innovation co-directs with the University of Toronto, is accepting applications for Cohort 4. The full application is available on the UTEST website.
 In meantime, it’s our pleasure to reprint Brianna Goldberg’s “day-in-the-life-of-an-entrepreneur” feature on Cohort 3 company Nvest, published for U of T News.

Jackie Yan focuses on tweaking his PowerPoint slide deck despite the chaos unfolding around him.

Nvest team at work in front of a computer

Near the entrance to the office space he shares with teams from the six other startups that are part of the UTEST accelerator program, a phone spits distorted tones of an investment-related conference call at Hanna Tomory, CEO of a fatigue-management start-up called Syncadian, as she scratches a list of notes.

A few steps down the hall, Marissa Wu, founder of the digital sports coaching wearable startup called Onyx Motion, goes over presentation notes with her co-founder Vivek Kesarwani. They discuss the finer points of athlete training with the intensity of so many layup drills performed on the basketball net propped against the wall of their desk space.

Across the table in the conference room where Yan is feverishly editing his slides, James McCrae pieces together 3D sculptures of horses, wasps and dinosaurs created with software from his start-up, FlatFab.

“We’re hoping to make more stable structures with our 1.0 design, maybe integrating finger-joints,” McCrae explains as he prepares to demo FlatFab’s wares for a video crew from the Privy Council Office in Ottawa, Ontario.

The videographers are producing a video about MaRS Innovation today, which co-directs the UTEST accelerator program with the University of Toronto, and are capturing b-roll of UTEST founders at work on their ventures. With seven companies currently sharing the working space, there’s always something happening.

Continue Reading

Portfolio round-up: UTEST, Nvest and Whirlscape news

utestSometimes there’s so much happening with the MaRS Innovation portfolio that it’s hard to stay on top of all the news. Here are a few UTEST program stories that we missed in February.

  • UTEST was named to FundThrough.com’s list of “6 Exciting Canadian Startup Accelerators to Watch in 2015.” Program co-directors Mike Betts and Kurtis Scissons point out that UTEST does take an equity position in the incubated companies and does not run on a grant basis as mentioned in the article. (It’s a sweetheart deal, but not that sweet.)
  • Nvest LogoUTEST company Nvest was featured in a Globe and Mail story, “Next big sector to face disruption? Financial services” by Brenda Bouw. Here’s a quote:
    “Another emerging fintech startup is Nvest, an early-stage, crowd-sourced stock recommendation platform. Nvest compiles recommendations from its users, many of which are average retail investors, and builds a performance history others can track. The credibility of recommendations is based on a user’s past performance. Nvest co-founder Fredrick Zhou likens it to LinkedIn for stock recommendations. ‘Nvest is a place where investors post their trading resume.’ Investors are taking notice. Nvest recently received funding from the University of Toronto Early Stage Technology program and it is in the process of pitching the business to angel investors.”
Continue Reading

Holland Bloorview’s Anxiety Meter included in Globe and Mail’s neuroscience feature

Holland Bloorview Kids Rehab“Research labs across Ontario are full of ingenious – and even life-saving – inventions. Unfortunately, many of them never make it to market,” writes Wendy Leung in “These six great neuroscience ideas could make the leap from lab to market” in the November 20, 2014 edition of the Globe and Mail.

MaRS Innovation, which was created to help researchers solve exactly this problem, has a project with Holland Bloorview Kids Rehabilitation Hospital that was featured in Leung’s article. Asim Siddiqi founded the anxiety meter app for children with autism.

Siddiqi recently competed in the Ontario Brain Institute’s OBI Entrepreneurs Program, funded in part by the Ontario Centres of Excellence.

Here’s an excerpt:

As much as 80 per cent of children with autism suffer from anxiety, but they often have trouble recognizing and communicating their anxiety states, Siddiqi explains. “Just like we sometimes have difficulty ourselves recognizing when we’re kind of stress-eating and things like that, they have it a little worse than we do.”

Using sensors on the body, Dymaxia’s anxiety meter picks up physiological signals, such as heart rate and skin conductance – or the amount of electric current that passes through sensors on the skin, which increases with stress and body temperature. It then processes those signals and provides feedback of the child’s anxiety state in real time on a mobile phone or tablet.

Continue Reading

Xagenic’s Shana Kelley named to Globe and Mail’s Top 12 Canadian Innovators

Xagenic 2014 logoDr. Shana Kelley, co-founder of Xagenic Inc. and a professor of biochemistry at the University of Toronto, has been named to the Globe and Mail’s Top 12 Canadian Innovators list.

The contest solicited nominations from across Canada that were assessed by a panel of judges. According to the Globe, the contest “recognizes talented Canadians who not only have great ideas, but also turn them into reality.”

Here’s an excerpt:

Another innovator who is taking on the traditional way of doing things is Ms. Kelley, a winner in the Health category. Ms. Kelley, a University of Toronto professor and founder of Xagenic, developed a lab-free molecular diagnostic platform that can test for cancer and infectious diseases in the field, with results that are available in 20 minutes.

It’s a product, says Mr. [Dan] Debow, [senior vice-president of emerging technologies at Salesforce] that is in line with a bigger trend that’s happening in health care: the decentralization and democratization of diagnostics.

Continue Reading

Globe and Mail: Strong incubators are key to driving innovation

utestJeff Cates’ op-ed in the Globe and Mail‘s Small Business/Digital Innovation section on June 19, 2014 argues that incubators have a key role to play in fostering innovation, entrepreneurship and growing new industries in Ontario.

Cates states this is particularly true when incubators when they provide programs and services to help young entrepreneurs succeed.

The University of Toronto Early-Stage Technology program (UTEST), co-managed with MaRS Innovation, is one such program. UTEST is set to announce its third cohort within the next month.

Continue Reading

Frost & Sullivan awards Xagenic award for new product innovation leadership

Market research company lauds start-up for developing a breakthrough workflow while dramatically improving point-of-care diagnosis

Xagenic 2014 logo(MOUNTAIN VIEW, Calif) May 20, 2014 — Based on its recent analysis of the point-of-care diagnostics market, Frost & Sullivan recognizes Xagenic Inc. with the 2014 North America Frost & Sullivan Award for New Product Innovation Leadership.

Xagenic’s revolutionary product, the Xagenic X1™ system, is a point-of-care platform with intuitive features to provide lab-free molecular diagnostic testing. It is unique as a low-cost, simple, rapid sample-to-answer desktop instrument, requiring no manual sample processing or cold storage. Currently, the platform is in the beta-testing phase and is expected to launch between 2015 and 2016.

Dr. Shana Kelley and Xagenic were featured in the Globe and Mail on May 20, 2014.

Read the detailed Frost & Sullivan Best Practices Research Report report on Xagenic’s website. Xagenic is MaRS Innovation’s lead start-up company, in partnership with the University of Toronto: Xagenic news archive.

For its portfolio of cartridge-based tests, Xagenic focuses on infectious diseases (HSV 1+2, Flu A+B, CT/NG, strep A, group B strep, trichomoniasis, HCV and upper respiratory infections) that will benefit the most from rapid on-site testing. The company also intends to apply the platform to counter a critical public health threat—antimicrobial resistance.

Continue Reading

WaveCheck breast cancer technology receives $100,000

OICR’s catalyst grant enables WaveCheck to open first partner site at MD Anderson Cancer Center in May

WavecheckTORONTO, April 8, 2014 — People with breast cancer are a step closer to knowing if their tumour is responding to chemotherapy at the start of treatment, thanks to a $100,000 catalyst grant from the Ontario Institute for Cancer Research (OICR).

The funding builds upon MaRS Innovation‘s Indiegogo crowdfunding campaign for WaveCheck, which successfully raised over $50,000 from over 500 supporters worldwide in two months last fall.

Read Jane Gerster’s article for the Toronto Star about OICR’s catalyst grant for WaveCheck. This announcement was also covered in Metro, BetaKit and Council of Academic Hospitals of Ontario’s Catalyst newsletter.

WaveCheck, a clinical technique invented, refined and tested by scientists at Sunnybrook Health Sciences Centre and Ryerson University over 20 years, aims to show whether chemotherapy is actually destroying a breast cancer tumour at the beginning of chemotherapy treatment (in as little as four weeks), rather than at the end of treatment (typically four to six months).

In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology (shown here) shows promise as an accurate, efficient way to monitor tumour response. Sunnybrook has partnered with GE Healthcare to co-develop WaveCheck as a clinical tool.
In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology (shown here) shows promise as an accurate, efficient way to monitor tumour response. As of March 2015, Sunnybrook has partnered with GE Healthcare to co-develop WaveCheck as a clinical tool.

In early clinical testing, the non-invasive, image-guided technology has shown promise as an accurate, efficient way to monitor tumour response, opening the door to tailored treatment.

“This is a significant step towards achieving the goal of personalized medicine. The clinical trials will confirm that information provided by WaveCheck can determine if the treatment is the appropriate one or that other options should be chosen, sparing patients the side effects of treatments that will not likely be successful,” said Dr. Tom Hudson, OICR’s president and scientific director. “If successful, WaveCheck could become a standard tool in the cancer treatment of the future.”

Continue Reading
Back To Top